Phaseline

Targets › IL2RA

IL2RA (Interleukin-2 receptor subunit alpha): drug programs, companies and trials

26 programs from 24 companies in 45 trials: 21 Phase 1, 18 Phase 2, 5 Phase 3, 1 Phase 4; Oncology, Metabolic and endocrine, Immunology; next expected readout Nov 2026.

Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. (UniProt, P01589)

Open in Phaseline: the race on IL2RA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing Children's Hospitalrecombinant humanized anti-CD25 monoclonal antibody
anti-CD25 monoclonal antibody
IL2RAPhase 4EBV-T/NK LPDOct 2029
Nektar TherapeuticsRezpegaldesleukin (NKTR-358)
Pegylated recombinant human interleukin-2
IL2RA, IL2Phase 3Moderate-to-Severe Atopic Dermatitis; Moderate to Severe Atopic Dermatitis; Type 1 Diabetes MellitusDec 2026
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDaclizumab (CD25)
Interleukin-2 receptor inhibitor
IL2RA, IL2RG, IL2RBPhase 3Graft Versus Host DiseaseMay 2028
CellTransBasiliximab
Interleukin-2 receptor inhibitor
IL2RA, IL2RG, IL2RBPhase 3Type 1 Diabetes Mellitus; Renal Transplant Rejection; Recurrent Hodgkin Lymphoma; Acute Lymphoblastic Leukemia–
Dana-Farber Cancer InstituteAldesleukin
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 2Chronic Graft-versus-host Disease; Acute Myeloid Leukemia; Platinum-resistant Ovarian Cancer; Chronic Graft Versus Host DiseaseNov 2026
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSAldesleukin
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 2Stage IV Colorectal Cancer; Head Neck Tumors; Mesothelioma, MalignantDec 2026
Institute of Hematology & Blood Diseases Hospital, ChinaRecombinant Humanized Anti-CD25 Monoclonal Antibody Injection
Anti-CD25 monoclonal antibody
IL2RAPhase 2Acute Graft-versus-Host DiseaseDec 2026
SWOG Cancer Research NetworkNogapendekin Alfa (N-803, ALT-803)
IL-15/IL-15Rα fusion protein that activates natural killer cells
IL15, IL2RAPhase 2Advanced Lung Non-Small Cell CarcinomaJun 2027
Shanxi Bethune HospitalRecombinant Humanized Anti-CD25 Monoclonal Antibody
Anti-CD25 monoclonal antibody
IL2RAPhase 2Acute Myeloid LeukemiaAug 2027
Memorial Sloan Kettering Cancer CenterNKTR-214
CD25-targeted IL-2 cytokine prodrug
IL2RAPhase 2SARCOMASep 2027
Rongrong Liurecombinant humanized anti-CD25 monoclonal antibody
anti-CD25 monoclonal antibody
IL2RAPhase 2Transfusion Dependent ThalassemiaSep 2027
M.D. Anderson Cancer CenterAldesleukin
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 2Melanoma; Metastatic Melanoma; Metastatic Malignant Neoplasm in the LungOct 2027
Assistance Publique - Hôpitaux de ParisAldesleukin (ILT-101)
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 2Type 1 DiabetesNov 2027
Shanghai Pulmonary Hospital, Shanghai, ChinaIBI363
PD-1/IL-2α biased agonist
PDCD1, IL2RAPhase 2Unresectable Stage III Non-small Cell Lung CancerJun 2028
Regeneron PharmaceuticalsREGN10597
PD-1-IL2Ra-IL2 immunotherapy
PDCD1, IL2RA, IL2Phase 2Ovarian Cancer; Non Small Cell Lung Cancer; MelanomaJun 2028
Vall d'Hebron Institute of OncologyANV419
IL-2 receptor agonist analog
IL2RAPhase 2MelanomaSep 2029
PolTREGex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)
Ex vivo expanded regulatory T cell therapy
CD4, CD25, IL2RAPhase 2Presymptomatic Diabetes Type 1 (Stage 1)Dec 2032
Dana-Farber Cancer InstituteCD25hi Treg depleted DLI
Donor lymphocyte infusion with CD25-positive regulatory T cell depletion
IL2RAPhase 1Acute Myeloid LeukemiaDec 2026
AgonOxDP CD8 TIL KD
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 1HNSCCDec 2026
GI InnovationGI-108
Anti-CD73-IgG4 Fc-IL-2v bispecific fusion protein
CD73, IL2RAPhase 1Advanced Solid TumorFeb 2027
SynthekineSTK-009
human orthogonal IL-2 cytokine selective for hoRb-expressing CAR-T cells
IL2RAPhase 1Systemic Lupus Erythematosus; CLL/SLLApr 2028
Stanford UniversityPurified regulatory T-cells (Treg) plus CD34+ HSPC
Enriched regulatory T-cell graft engineering to reduce GVHD while maintaining graft functi
IL2RAPhase 1Allogeneic Hematopoietic Cell Transplantation (HCT)May 2028
Stanford UniversityDonor Hematopoietic Stem Cells and Recipient Tregs
Donor CD34+ hematopoietic stem cells combined with recipient regulatory T cells to facilit
CD34, IL2RAPhase 1Glioma of Spinal Cord; Living Donor Kidney TransplantationJul 2028
H. Lee Moffitt Cancer Center and Research InstituteInterleukin-2 (IL-2)
Cytokine to support TIL expansion and activation
IL2RA, IL2RB, IL2RGPhase 1LymphocytesSep 2029
Alexander B Olawaiye, MDDenileukin Diftitox (E7777)
Elongation factor 2 inhibitor; Interleukin-2 receptor binding agent
EEF2, IL2RA, IL2RG, IL2RBPhase 1Epithelial Ovarian CancerMay 2030
Mural OncologyNemvaleukin alfa (ALKS 4230)
IL-2 receptor agonist
IL2RAPhase 1Advanced Solid Tumor–

Conditions

Acute Myeloid Leukemia (5) Melanoma (3) Moderate-to-Severe Atopic Dermatitis (2) Type 1 Diabetes Mellitus (2) Advanced Solid Tumor (2) Acute Graft-versus-Host Disease (1) Metastatic Melanoma (1) Metastatic Malignant Neoplasm in the Lung (1) Chronic Graft-versus-host Disease (1) Platinum-resistant Ovarian Cancer (1) Chronic Graft Versus Host Disease (1) Transfusion Dependent Thalassemia (1)

Modalities

mixed (12), protein or peptide (5), small molecule (4), antibody (3), other (1)

Companies

Dana-Farber Cancer Institute (2) Stanford University (2) Institute of Hematology & Blood Diseases Hospital, China (1) M.D. Anderson Cancer Center (1) Vall d'Hebron Institute of Oncology (1) Rongrong Liu (1) Alexander B Olawaiye, MD (1) Nektar Therapeutics (1) Shanxi Bethune Hospital (1) Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) Regeneron Pharmaceuticals (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Mural Oncology (1) Assistance Publique - Hôpitaux de Paris (1) Memorial Sloan Kettering Cancer Center (1) PolTREG (1) SWOG Cancer Research Network (1) H. Lee Moffitt Cancer Center and Research Institute (1) GI Innovation (1) Synthekine (1)

Related targets

IL2RG (9) IL2RB (9) IL2 (2) PDCD1 (2) EEF2 (1) CD34 (1) CD4 (1) CD25 (1) IL15 (1) CD73 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.